WO2023078868 - CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR
National phase entry:
Publication Number
WO/2023/078868
Publication Date
11.05.2023
International Application No.
PCT/EP2022/080434
International Filing Date
01.11.2022
Title **
[English]
CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR
[French]
FORMES CRISTALLINES D'UN INHIBITEUR DE MONOACYLGLYCÉROL LIPASE
Applicants **
H. LUNDBECK A/S
9, Ottiliavej
2500 Valby, DK
Inventors
ANDREW, Samuel George
c/o H. Lundbeck
9, Ottiliavej
2500 Valby, DK
CINCOTTI, Antonio
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
PATTERSON, Adam Ross
c/o H. Lundbeck
9, Ottiliavej
2500 Valby, DK
EDWARDS, Richard James
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
VETTER, Thomas
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
JUHL, Martin
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
LOPEZ DE DIEGO, Heidi
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
GRICE, Cheryl A.
c/o H. Lundbeck A/S
2500 Valby, DK
WIENER, John J.M.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
BUZARD, Daniel J.
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
ALLAN, Amy
c/o H. Lundbeck A/S
9, Ottiliavej
2500 Valby, DK
GANCEDO, Susana Del Rio
c/o H. Lundbeck A/S
2500 Valby, DK
Priority Data
63/274,887
02.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1393 | |
| EPO | Filing, Examination | 5632 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5110 |
Total: 13305 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein is new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.[French]
L'invention concerne de nouvelles formes cristallines de l'inhibiteur de MAGL 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluorométhyl)benzyl)-1,8-diazaspiro[4,5]décane-8-carbonyl)-1H-pyrazole-3-carboxylique, ou d'un sel pharmaceutiquement acceptable de celui-ci.